Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28225545 | 0.88 | CYP3A4 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL1614609 | 0.88 | CYP3A4 (0.73) | CYP3A4MAPK1USP2SMN1; SMN2ABCG2 | |
| SCHEMBL6507929 | 0.88 | SMN1; SMN2 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL311761 | 0.88 | KMT2A (0.57) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL1012409 | 0.86 | CYP3A4 (0.51) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL31335763 | 0.86 | CYP3A4 (0.51) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL18170324 | 0.86 | MAPK1 (0.51) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL30486448 | 0.85 | CYP3A4 (0.50) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| SCHEMBL29109689 | 0.85 | CYP3A4 (0.50) | CYP3A4MAPK1USP2SMN1; SMN2CA12 | |
| Hydrochloric Acid SCHEMBL4299984 | 0.85 | CYP3A4 (0.50) | CYP3A4MAPK1USP2SMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924306-A | Full-synthesis preparation method of wedelolactone or demethylwedelolactone | 中国药科大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117343615-A | Water-based UV positioning laser transfer coating and preparation method and application thereof | 湖南互力达涂料科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116041319-B | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116041319-A | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-106748604-B | Method for synthesizing mono-iodo aromatic hydrocarbon or di-iodo aromatic hydrocarbon based on decarboxylation of aromatic carboxylic acid | 湘潭大学 | 2020-06-05 | — | — | CN | claimed |
| CN-106748604-A | A kind of method for synthesizing single iodo aromatic hydrocarbon or two iodo aromatic hydrocarbons based on aromatic carboxylic acid's decarboxylic reaction | 湘潭大学 | 2017-05-31 | — | — | CN | claimed |
| US-7196214-B2 | Process for arylamine production | XEROX CORPORATION (US) | 2007-03-27 | — | — | US | claimed |
| US-20060111582-A1 | Process for arylamine production | XEROX CORPORATION (US) | 2006-05-25 | — | — | US | claimed |
| US-20040147493-A1 | Synergistic compositions for the selective control of tumor tissue | KREUTZ WERNER | 2004-07-29 | — | — | US | claimed |
| US-20030166621-A1 | Synergistic mixture comprising benzoic acid derivatives for use as anticarcinogenic agents, antitumor agents | KREUTZ WERNER (DE) | 2003-09-04 | — | — | US | claimed |
| EP-1001756-A1 | SYNERGISTICALLY ACTING COMPOSITIONS FOR SELECTIVELY COMBATING TUMOR TISSUE | Kreutz, Werner, Prof. Dr. (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-1998058639-A1 | SYNERGISTICALLY ACTING COMPOSITIONS FOR SELECTIVELY COMBATING TUMOR TISSUE | KREUTZ WERNER (DE) | 1998-12-30 | — | — | WO | claimed |
| CN-117924306-B | Full-synthesis preparation method of wedelolactone or demethylwedelolactone | 中国药科大学 | 2025-09-16 | — | — | CN | disclosed |
| CN-118702589-A | Method for synthesizing tertiary amide in aqueous phase | 常州合全药业有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117924306-A | Full-synthesis preparation method of wedelolactone or demethylwedelolactone | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924306-A | Full-synthesis preparation method of wedelolactone or demethylwedelolactone | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| US-4247597-A | Electroscopic carrier particles having a carboxylic acid surface treatment | PITNEY BOWES, INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4230696-A | CONTAINING GLYCINE AND LYSINE OR ARGININE | ST. LUKE'S HOSPITAL (US) | 1980-10-28 | — | — | US | disclosed |
| US-4075167-A | MALEIMIDO GROUP-CONTAINING ORGANOSILICON COMPOUNDS | DAI NIPPON PRINTING CO., LTD. (JA) | 1978-02-21 | — | — | US | disclosed |
| US-4019904-A | INK REPELLENT | DAI NIPPON PRINTING COMPANY LIMITED (JA) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111582-A1 | Process for arylamine production | AOC2, UFM1, TYR | CYP3A4 85/4885MAPK1 2706/4885USP2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.